The Process

Working together, StarFish Medical and Pyng Medical Corp. engaged with key military and civilian customers and end-users to identify the strengths and weaknesses of the FAST1® product. Preliminary research was followed up with focus groups of emergency medicine thought-leaders to corroborate the initial findings from the field. StarFish created a Product Definition using the insights gathered for a next generation IO device

The Results

Updating the military device for civilian appeal also makes the FASTResponder™ a more useful device on the battlefield. Less needles with a mechanical redesign that shields them in a transparent plastic shell creates an easier to handle device and improves civilian end-user perceptions. Reducing the size, weight, appearance and the force required for insertion allowed a more intuitive and ergonomic product appropriate for all civilian providers. Together, StarFish Medical and Pyng Medical Corp took the FASTResponder™ product through the requirements testing process.

Bottom Line

FASTResponder™, Pyng Medical Corps. next generation IO Infusion device, received the CE Mark in Europe, is cleared by the United States Food and Drug Administration (FDA) for marketing in the United States and cleared by Health Canada. The FASTResponder™ product has received initial positive input from medical professionals for being easy to learn and easy to use.